Progression risks , adverse event probabilities , costs , and utilities were estimated from clinical data of Primary RItuximab and MAintenance ( PRIMA ) trial , Eastern Cooperative Oncology Group ( ECOG ) trial ( for MR ) , and First-line Indolent Trial ( for RIT ) and the published literature .